Vis enkel innførsel

dc.contributor.authorCurrie, Crawford
dc.contributor.authorFramroze, Bomi
dc.contributor.authorSingh, Dave
dc.contributor.authorLea, Simon
dc.contributor.authorBjerknes, Christian
dc.contributor.authorHermansen, Erland
dc.date.accessioned2022-11-30T13:11:22Z
dc.date.available2022-11-30T13:11:22Z
dc.date.created2022-11-05T21:25:51Z
dc.date.issued2022-10-14
dc.identifier.issn2227-9059
dc.identifier.urihttps://hdl.handle.net/11250/3035084
dc.description.abstractEosinophils are a major driver of inflammation in a number of human diseases, including asthma. Biologic therapies targeting IL-5 have enabled better control of severe eosinophilic asthma, but no such advances have been made for enhancing the control of moderate asthma. However, a number of moderate asthma sufferers remain troubled by unresolved symptoms, treatment side effects, or both. OmeGo, an enzymatically liberated fish oil, has demonstrated antioxidant and anti-inflammatory properties including the reduction of eosinophilia. A house dust mite model of induced asthma in mice was utilized in this study, and OmeGo showed a significant reduction in eosinophilic lung and systemic inflammation and reduced lung remodelling compared to cod liver oil. The CRTH2 antagonist fevipiprant showed an anti-inflammatory profile similar to that of OmeGo. OmeGo has the potential to be a pragmatic, cost-effective co-treatment for less severe forms of eosinophilic asthma. Proof-of-concept studies are planned.en_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleAssessing the Anti-Inflammatory Effects of an Orally Dosed Enzymatically Liberated Fish Oil in a House Dust Model of Allergic Asthmaen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2022 the authorsen_US
dc.source.articlenumber2574en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.3390/biomedicines10102574
dc.identifier.cristin2069548
dc.source.journalBiomedicinesen_US
dc.identifier.citationBiomedicines. 2022, 10 (10), 2574.en_US
dc.source.volume10en_US
dc.source.issue10en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal